Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor.

Ligand binding to estrogen receptor (ER) is presumed to regulate the type and timing of ER interactions with different cofactors. Using fluorescence microscopy in living cells, we characterized the recruitment of five different green fluorescent protein (GFP)-labeled ER-interacting peptides to the distinct subnuclear compartment occupied by blue fluorescent protein (BFP)-labeled ER alpha. Different ligands promoted the recruitment of different peptides. One peptide was recruited in response to estradiol (E2), tamoxifen, raloxifene, or ICI 182,780 incubation whereas other peptides were recruited specifically by E2 or tamoxifen. Peptides containing different sequences surrounding the ER-interacting motif LXXLL were recruited with different time courses after E2 addition. Complex temporal kinetics also were observed for recruitment of the full-length, ER cofactor glucocorticoid receptor-interacting protein 1 (GRIP1); rapid, E2-dependent recruitment of GRIP1 was blocked by mutation of the GRIP1 LXXLL motifs to LXXAA whereas slower E2 recruitment persisted for the GRIP1 LXXAA mutant. This suggested the presence of multiple, temporally distinct GRIP 1 recruitment mechanisms. E2 recruitment of GRIP1 and LXXLL peptides was blocked by coincubation with excess ICI 182,780. In contrast, preformed E2/ER/GRIP1 and E2/ER/LXXLL complexes were resistant to subsequent ICI 182,780 addition whereas ICI 182,780 dispersed preformed complexes containing the GRIP1 LXXAA mutant. This suggested that E2-induced LXXLL binding altered subsequent ligand/ER interactions. Thus, alternative, ligand-selective recruitment and dissociation mechanisms with distinct temporal sequences are available for ER alpha action in vivo.

[1]  J. Northrop,et al.  Selection of Estrogen Receptor β- and Thyroid Hormone Receptor β-Specific Coactivator-Mimetic Peptides Using Recombinant Peptide Libraries , 2000 .

[2]  S. Mosselman,et al.  Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. , 2000, Molecular endocrinology.

[3]  Carolyn L. Smith,et al.  Subnuclear Trafficking of Estrogen Receptor-α and Steroid Receptor Coactivator-1 , 2000 .

[4]  T. Pederson,et al.  Half a century of "the nuclear matrix". , 2000, Molecular biology of the cell.

[5]  D. Fowlkes,et al.  Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors α and β , 1999, Molecular and Cellular Biology.

[6]  B. Katzenellenbogen,et al.  Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. , 1999, Molecular endocrinology.

[7]  R. Evans,et al.  Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase , 1999, Cell.

[8]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[9]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[10]  F. Schaufele Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins. , 1999, Molecular endocrinology.

[11]  M. Morrow,et al.  Tamoxifen, raloxifene, and the prevention of breast cancer. , 1999, Endocrine reviews.

[12]  Paul Tempst,et al.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.

[13]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Hager,et al.  Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras. , 1999, Molecular endocrinology.

[15]  J. Davie,et al.  Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor. , 1999, Molecular biology of the cell.

[16]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[17]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[18]  C. Glass,et al.  Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.

[19]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[20]  B. Katzenellenbogen,et al.  Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.

[21]  R. Day,et al.  Visualization of Pit-1 transcription factor interactions in the living cell nucleus by fluorescence resonance energy transfer microscopy. , 1998, Molecular endocrinology.

[22]  G. Stein,et al.  Interrelationships of nuclear structure and transcriptional control: Functional consequences of being in the right place at the right time , 1998, Journal of cellular biochemistry.

[23]  R. Roeder,et al.  The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R J Fletterick,et al.  Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. , 1998, Science.

[25]  G. Colditz,et al.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.

[26]  D. Pearce,et al.  Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular endocrinology.

[28]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[29]  J. Baxter,et al.  Activities in Pit-1 determine whether receptor interacting protein 140 activates or inhibits Pit-1/nuclear receptor transcriptional synergy. , 1997, Molecular endocrinology.

[30]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[31]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[32]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[33]  V. Jordan,et al.  Risks and benefits of tamoxifen therapy. , 1997, Oncology.

[34]  G. Hager,et al.  Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Tsien,et al.  Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer , 1996, Current Biology.

[37]  B. Katzenellenbogen,et al.  Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.

[38]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[39]  B. van Steensel,et al.  Localization of the glucocorticoid receptor in discrete clusters in the cell nucleus. , 1995, Journal of cell science.

[40]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[41]  M. Gossen,et al.  Transcriptional activation by tetracyclines in mammalian cells. , 1995, Science.

[42]  R. Fletterick,et al.  The Molecular Biology of Thyroid Hormone Action , 1995, Annals of the New York Academy of Sciences.

[43]  P. Webb,et al.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.

[44]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[45]  M. Ko,et al.  The dose dependence of glucocorticoid‐inducible gene expression results from changes in the number of transcriptionally active templates. , 1990, The EMBO journal.

[46]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[47]  C. Benham,et al.  Transcriptional augmentation: modulation of gene expression by scaffold/matrix-attached regions (S/MAR elements). , 2000, Critical reviews in eukaryotic gene expression.

[48]  K. Brown Nuclear structure, gene expression and development. , 1999, Critical reviews in eukaryotic gene expression.

[49]  Dana,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER a and ER b , 1999 .

[50]  H. Gronemeyer,et al.  Therapeutic potential of selective modulators of nuclear receptor action. , 1998, Current opinion in chemical biology.

[51]  J. Gustafsson,et al.  Therapeutic potential of selective estrogen receptor modulators. , 1998, Current opinion in chemical biology.

[52]  F. Schaufele CCAAT/Enhancer-binding Protein (cid:97) Activation of the Rat Growth Hormone Promoter in Pituitary Progenitor GHFT1-5 Cells* , 1996 .

[53]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.